635 related articles for article (PubMed ID: 27191954)
1. Pemetrexed/Carboplatin/Bevacizumab followed by Maintenance Pemetrexed/Bevacizumab in Hispanic Patients with Non-Squamous Non-Small Cell Lung Cancer: Outcomes according to Thymidylate Synthase Expression.
Cardona AF; Rojas L; Wills B; Arrieta O; Carranza H; Vargas C; Otero J; Cuello M; Corrales L; Martín C; Ortiz C; Franco S; Rosell R;
PLoS One; 2016; 11(5):e0154293. PubMed ID: 27191954
[TBL] [Abstract][Full Text] [Related]
2. Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer.
Patel JD; Hensing TA; Rademaker A; Hart EM; Blum MG; Milton DT; Bonomi PD
J Clin Oncol; 2009 Jul; 27(20):3284-9. PubMed ID: 19433684
[TBL] [Abstract][Full Text] [Related]
3. Maintenance therapy with pemetrexed and bevacizumab versus pemetrexed monotherapy after induction therapy with carboplatin, pemetrexed, and bevacizumab in patients with advanced non-squamous non small cell lung cancer.
Karayama M; Inui N; Fujisawa T; Enomoto N; Nakamura Y; Kuroishi S; Yokomura K; Koshimizu N; Sato M; Toyoshima M; Shirai T; Masuda M; Yamada T; Imokawa S; Suda T
Eur J Cancer; 2016 May; 58():30-7. PubMed ID: 26922170
[TBL] [Abstract][Full Text] [Related]
4. A phase II study of carboplatin, pemetrexed, and bevacizumab followed by erlotinib and bevacizumab maintenance for non-squamous non-small cell lung cancer with wild-type EGFR (HOT1101).
Takashina T; Asahina H; Oizumi S; Yamada N; Harada M; Takamura K; Yokouchi H; Harada T; Honjo O; Ogi T; Morikawa N; Kinoshita I; Honda R; Nakano K; Kanazawa K; Amano T; Dosaka-Akita H; Isobe H; Nishimura M;
Int J Clin Oncol; 2018 Dec; 23(6):1060-1069. PubMed ID: 30027464
[TBL] [Abstract][Full Text] [Related]
5. Phase II Trial of Carboplatin and Pemetrexed Plus Bevacizumab with Maintenance Bevacizumab as a First-line Treatment for Advanced Non-squamous Non-small Cell Lung Cancer in Elderly Patients.
Takeoka H; Yamada K; Naito Y; Matsuo N; Ishii H; Tokito T; Azuma K; Ichiki M; Hoshino T
Anticancer Res; 2018 Jun; 38(6):3779-3784. PubMed ID: 29848743
[TBL] [Abstract][Full Text] [Related]
6. Carboplatin/pemetrexed/bevacizumab in the treatment of patients with advanced non-small-cell lung cancer: a single-institution experience.
Malhotra B; Evans T; Weiss J; Eaby B; Stonehouse-Lee S; Sherry V; Langer CJ
Clin Lung Cancer; 2010 May; 11(3):192-7. PubMed ID: 20439196
[TBL] [Abstract][Full Text] [Related]
7. An Exploratory Randomized Phase II Trial Comparing CDDP Plus S-1 With Bevacizumab and CDDP Plus Pemetrexed With Bevacizumab Against Patients With Advanced Non-squamous Non-small Cell Lung Cancer.
Kaira K; Imai H; Souma R; Sakurai R; Miura Y; Sunaga N; Kasahara N; Tsukagoshi Y; Koga Y; Kitahara S; Kotake M; Minato K; Naruse I; Fukushima Y; Hisada T; Ishizuka T
Anticancer Res; 2019 May; 39(5):2483-2491. PubMed ID: 31092443
[TBL] [Abstract][Full Text] [Related]
8. A phase II study of bevacizumab with carboplatin-pemetrexed in non-squamous non-small cell lung carcinoma patients with malignant pleural effusions: North East Japan Study Group Trial NEJ013A.
Usui K; Sugawara S; Nishitsuji M; Fujita Y; Inoue A; Mouri A; Watanabe H; Sakai H; Kinoshita I; Ohhara Y; Maemondo M; Kagamu H; Hagiwara K; Kobayashi K;
Lung Cancer; 2016 Sep; 99():131-6. PubMed ID: 27565928
[TBL] [Abstract][Full Text] [Related]
9. PointBreak: a randomized phase III study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer.
Patel JD; Socinski MA; Garon EB; Reynolds CH; Spigel DR; Olsen MR; Hermann RC; Jotte RM; Beck T; Richards DA; Guba SC; Liu J; Frimodt-Moller B; John WJ; Obasaju CK; Pennella EJ; Bonomi P; Govindan R
J Clin Oncol; 2013 Dec; 31(34):4349-57. PubMed ID: 24145346
[TBL] [Abstract][Full Text] [Related]
10. Switch maintenance therapy with docetaxel and bevacizumab after induction therapy with cisplatin, pemetrexed, and bevacizumab in advanced non-squamous non-small cell lung cancer: a phase II study.
Nishimoto K; Karayama M; Inui N; Yasui H; Hozumi H; Suzuki Y; Furuhashi K; Fujisawa T; Enomoto N; Nakamura Y; Inami N; Matsuura S; Kaida Y; Matsui T; Asada K; Matsuda H; Fujii M; Toyoshima M; Imokawa S; Suda T
Med Oncol; 2018 Jun; 35(7):108. PubMed ID: 29909581
[TBL] [Abstract][Full Text] [Related]
11. Multicenter phase II study on cisplatin, pemetrexed, and bevacizumab followed by maintenance with pemetrexed and bevacizumab for patients with advanced or recurrent nonsquamous non-small cell lung cancer: MAP study.
Tsutani Y; Miyata Y; Masuda T; Fujitaka K; Doi M; Awaya Y; Kuyama S; Kitaguchi S; Ueda K; Hattori N; Okada M
BMC Cancer; 2018 Dec; 18(1):1231. PubMed ID: 30526545
[TBL] [Abstract][Full Text] [Related]
12. Thymidylate synthase expression and outcome of patients receiving pemetrexed for advanced nonsquamous non-small-cell lung cancer in a prospective blinded assessment phase II clinical trial.
Nicolson MC; Fennell DA; Ferry D; O'Byrne K; Shah R; Potter V; Skailes G; Upadhyay S; Taylor P; André V; Nguyen TS; Myrand SP; Visseren-Grul C; Das M; Kerr KM
J Thorac Oncol; 2013 Jul; 8(7):930-9. PubMed ID: 23722170
[TBL] [Abstract][Full Text] [Related]
13. Results of a Phase II Trial of Carboplatin, Pemetrexed, and Bevacizumab for the Treatment of Never or Former/Light Smoking Patients With Stage IV Non-Small Cell Lung Cancer.
Weiss JM; Villaruz LC; O'Brien J; Ivanova A; Lee C; Olson JG; Pollack G; Gorman R; Socinski MA; Stinchombe TE
Clin Lung Cancer; 2016 Mar; 17(2):128-32. PubMed ID: 26774201
[TBL] [Abstract][Full Text] [Related]
14. NCCTG N0821 (Alliance): a phase II first-line study of pemetrexed, carboplatin, and bevacizumab in elderly patients with advanced nonsquamous non-small-cell lung cancer with good performance status.
Dy GK; Molina JR; Qi Y; Ansari R; Thomas S; Ross HJ; Soori G; Anderson D; Aubry MC; Meyers J; Adjei AA; Mandrekar S; Adjei AA
J Thorac Oncol; 2014 Aug; 9(8):1146-53. PubMed ID: 25157767
[TBL] [Abstract][Full Text] [Related]
15. Clinical option of pemetrexed-based versus paclitaxel-based first-line chemotherapeutic regimens in combination with bevacizumab for advanced non-squamous non-small-cell lung cancer and optimal maintenance therapy: evidence from a meta-analysis of randomized control trials.
Huang LT; Cao R; Wang YR; Sun L; Zhang XY; Guo YJ; Zhao JZ; Zhang SL; Jing W; Song J; Han CB; Ma J
BMC Cancer; 2021 Apr; 21(1):426. PubMed ID: 33865364
[TBL] [Abstract][Full Text] [Related]
16. A phase II study of pemetrexed plus carboplatin followed by maintenance pemetrexed as first-line chemotherapy for elderly patients with advanced non-squamous non-small cell lung cancer.
Tamiya M; Tamiya A; Kaneda H; Nakagawa K; Yoh K; Goto K; Okamoto H; Shimokawa T; Abe T; Tanaka H; Daga H; Takeda K; Hirashima T; Atagi S
Med Oncol; 2016 Jan; 33(1):2. PubMed ID: 26603297
[TBL] [Abstract][Full Text] [Related]
17. A phase 2 study of bevacizumab in combination with carboplatin and paclitaxel in patients with non-squamous non-small-cell lung cancer harboring mutations of epidermal growth factor receptor (EGFR) after failing first-line EGFR-tyrosine kinase inhibitors (HANSHIN Oncology Group 0109).
Hattori Y; Satouchi M; Shimada T; Urata Y; Yoneda T; Mori M; Nishimura T; Sunadome H; Kumagai T; Imamura F; Fujita S; Kaji R; Hata A; Tachihara M; Morita S; Negoro S
Lung Cancer; 2015 Feb; 87(2):136-40. PubMed ID: 25553650
[TBL] [Abstract][Full Text] [Related]
18. Pemetrexed, oxaliplatin and bevacizumab as first-line treatment in patients with stage IV non-small cell lung cancer.
Mir O; Boudou-Rouquette P; Giroux J; Chapron J; Alexandre J; Gibault L; Ropert S; Coriat R; Durand JP; Burgel PR; Dusser D; Goldwasser F
Lung Cancer; 2012 Jul; 77(1):104-9. PubMed ID: 22364783
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of carboplatin and pemetrexed in advanced non-squamous, non-small-cell lung cancer: Kyoto Thoracic Oncology Research Group Trial 0902.
Kim YH; Hirabayashi M; Togashi Y; Hirano K; Tomii K; Masago K; Kaneda T; Yoshimatsu H; Otsuka K; Mio T; Tomioka H; Suzuki Y; Mishima M
Cancer Chemother Pharmacol; 2012 Aug; 70(2):271-6. PubMed ID: 22752216
[TBL] [Abstract][Full Text] [Related]
20. PRONOUNCE: randomized, open-label, phase III study of first-line pemetrexed + carboplatin followed by maintenance pemetrexed versus paclitaxel + carboplatin + bevacizumab followed by maintenance bevacizumab in patients ith advanced nonsquamous non-small-cell lung cancer.
Zinner RG; Obasaju CK; Spigel DR; Weaver RW; Beck JT; Waterhouse DM; Modiano MR; Hrinczenko B; Nikolinakos PG; Liu J; Koustenis AG; Winfree KB; Melemed SA; Guba SC; Ortuzar WI; Desaiah D; Treat JA; Govindan R; Ross HJ
J Thorac Oncol; 2015 Jan; 10(1):134-42. PubMed ID: 25371077
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
